Please login to the form below
White paper for download: The vicious circle of pharmaceutical tendering
In this white paper, we discuss the pros of tendering, including cost reduction, but also the cons, such as supply issues and aggressive bidding consequences. Plus, our expert offers guidance on how to navigate the vicious circle.
With the tendering process becoming increasingly important in pharmaceutical procurement, accounting for around 25% of total global pharmaceutical turnover, it’s important to understand the impacts and risks that could affect you. In this white paper, we discuss the pros of tendering, including cost reduction, but also the cons, such as supply issues and aggressive bidding consequences. Plus, our expert offers guidance on how to navigate the vicious circle.
Download the white paper now for insight into:
- What tendering entails
- The importance of tendering for pharma
- The effect of epoetin tendering
- How the ‘winner takes all’ pricing game works
- The risks that create a vicious circle of tendering
Download the white paper here: https://www.validinsight.com/resource-center/the-vicious-circle-of-pharmaceutical-tendering/
Company Details
Valid Insight
Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom
Latest content on this profile
- How do companies prepare for reimbursement?
- Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement.
Valid Insight
- The 'winner takes all' pricing game
- Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight
- RWE Blog 4: The place of real-world evidence in the market access strategy
- The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in Real-world challenges and real-world data, understanding the payer's perspective, in Payers use real-world data cautiously, and seeing the views of both advocates and opponents of RWE in Is real-world evidence the holy grail: Finding the balance.
Valid Insight
- RWE Blog 3: Is real-world evidence the holy grail
- We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use real-world data cautiously. In our third instalment, we’re looking at how to find the right balance in using RWE.
Valid Insight
- RWE Blog 2: Payers use real-world data cautiously
- Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously.
Valid Insight
- RWE Blog 1: Real-world challenges and real-world data
- This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access.
Valid Insight
